FTC set to file suit against Mallinckrodt for using monopoly to jack up drug prices

Mallinckrodt’s stock tumbles after the New York Post reported the FTC is preparing to file charges against Mallinckrodt, alleging that the drug maker used its monopoly status to jack up the price of a lupus and multiple sclerosis treatment.